Efficacy of a Targeted **Pigment-Correcting Spot Treatment Cream for Post**inflammatory Hyperpigmentation and Solar Lentigines in a 12-Week, Single-Center Clinical Study

Elizabeth T. Makino, BS, CCRA, MBA¹; Priscilla Huang, BA¹; Summer F. Acevedo, PhD²; Cristiane de Oliveira, PhD³; Rahul C. Mehta, PhD¹

¹Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA; ²SGS Inc., Richardson, TX, USA; ³SGS Inc., Phoenix, AZ, USA

OBJECTIVE

To assess the efficacy and tolerance of a novel targeted pigmentcorrecting spot treatment gel suspension cream (Spot Tx) when used over the course of 12 weeks by women with mild to moderate dark spots (ie, post-inflammatory hyperpigmentation [PIH]/acne marks and/or age spots/solar lentigines) on the face

CONCLUSIONS



Spot Tx, a novel targeted pigment-correcting spot treatment cream, provided significant improvement in dark spots from PIH/acne marks and age spots/ solar lentigines as early as week 2, with continued improvement through week 12 in a broad range of participant races, ethnicities, and skin types



Spot Tx was well tolerated, with mean tolerability scores less than 0.25 at all study visits



Participants reported an 85% overall satisfaction rate with Spot Tx at week 12

For additional information or to obtain a PDF of this poster



Scan QR code or use the following link to download an electronic version of this presentation and other Allergan Aesthetics and AbbVie 2023 Winter CDC scientific presentations

https://abbvie1.outsystemsenterprise.com/GMAEventPublications/ Assets.aspx?ConferenceId=528

QR code expiration: December 13, 2023.

To submit a medical question, please visit www.abbviemedinfo.com



llergan Aesthetics, an AbbVie Company, and the authors thank the participants

ner F. Acevedo and Cristiane de Oliveira are emplovees of SGS In riginally presented at the American Society for Dermatologic Surgery (ASDS) 2022 Annual Meeting, Denver, CO, October 6-10, 2022.

References

1. Plensdorf S, et al. Am Fam Physician. 2017;96:797-804. 2. Davis EC, Callender VD. J Clin Aesthet Dermatol. 2010;3:20-31.

3. Balkrishnan R. et al. Int J Dermatol. 2006:45:111-5.

Presented at the Winter Clinical Dermatology Conference (WCH23); Kohala Coast, HI; January 13-18, 2023

Allergan Aesthetics an AbbVie company

SYNOPSIS

- Hyperpigmentation (darkening of the skin) occurs when excess melanin deposits form, resulting in uneven skin color or tone¹
- Facial hyperpigmentation types include postinflammatory hyperpigmentation (PIH)/acne marks (acquired after cutaneous inflammation or injury) and age spots/solar lentigines (well-circumscribed lesions on sun-exposed surfaces of the skin)^{1,2}
- Facial hyperpigmentation can have a negative impact on quality of life, affecting psychological and emotional well-being^{1,3}
- We conducted a 12-week, single-center clinical trial in females aged 25 to 64 years with mild to moderate hyperpigmentation who had at least 1 PIH/acne mark or at least 1 age spot/solar lentigo



RESULTS


Participants and Treatment Characteristics

	PIH (n=19)	Age Spots (n=22)	
Race/Ethnicity, n (%)			
White/Caucasian	1 (5.3)	11 (50.0)	
Hispanic	7 (36.8)	5 (22.7)	
Black/African American	10 (52.6)	0	
Asian	1 (5.3)	4 (18.2)	
Native American/ Alaska Native	0	1 (4.5)	
Asian/Caucasian	0	1 (4.5)	
Fitzpatrick skin type, n (%)			
1	0	1 (4.5)	
Ш	0	9 (40.9)	
ш	0	10 (45.5)	
IV	10 (52.6)	2 (9.1)	
V	9 (47.4)	0	

High Levels of Self-perceived Effectiveness and Overall Improvement and Satisfaction With Continued Use of Spot Tx at Week 12


At Week 12, the Test Product..

reduced the size of my pigment spots improved the look of sun damage on my skin improved the overall appearance of my skin improved the appearance of uneven skin tone and discolorations improved the evenness of my skin tone faded even the most stubborn spots on my skin improved my overall texture and evenness reduced the appearance of pigment caused by acne reduced the appearance of my age spots reduced the appearance of my sun spots reduced the size and intensity of my uneven pigment



0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% % of Participants Agreed

METHODS **Study Design**



Graph inverted to show positive mean values for clarity in indicating improvement.

■ Week 2 ■ Week 4 ■ Week 8 ■ Week 12

*P≤0.018 vs baseline (Wilcoxon signed-rank test).

Study Assessments

- Investigator assessments (clinical grading) on a modified Griffiths scale: 0 [none], 1-3 [mild], 4-6 [moderate], 7-9 [severe]): overall hyperpigmentation, skin tone evenness, dark spot size, dark spot intensity, dark spot contrast
- Digital photography: VISIA-CR imaging
- Clinical grading of tolerability parameters (0 [none], 1 [mild], 2 [moderate], 3 [severe]): erythema, edema, dryness, burning, stinging, itching, peeling
- Participant self-assessment questionnaire: treatment satisfaction, effects of immediate and continued use, texture, application experience



0.25 at all study visits